Bruker Introduces the New CTX™ Portable XRF Analyzer

MUNICH, April 10, 2018 /PRNewswire/ — At Analytica 2018, Bruker today introduces the new CTX™ X-ray fluorescence (XRF) elemental analyzer. The portable Counter Top XRF (CTX) is small, light-weight, safety-interlocked, and battery operated. At less than 7 kilograms in weight, the self-contained CTX is truly portable, and has a small footprint of 14 cm in... Read more

University of Pittsburgh and Thermo Fisher Scientific Establish Pharmacogenomics Center of Excellence

University of Pittsburgh and Thermo Fisher Scientific Establish Pharmacogenomics Center of Excellence Collaboration will support translational research that demonstrates the value of PGx in precision medicine PITTSBURGH, April 5, 2018 /PRNewswire/ — Thermo Fisher Scientific and the University of Pittsburgh have established a new Pharmacogenomics (PGx) Center of Excellence that combines expertise and technology in genomics,... Read more

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Basel, 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel These additional data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines... Read more

Bio-Techne Expands RNAscope® ISH Automation – Facilitating Drug Discovery and Development

New and updated assays increase application areas and improve performance MINNEAPOLIS, March 21, 2018 /PRNewswire/ — Bio-Techne has expanded the automation capabilities of its popular Advanced Cell Diagnostics (ACD)-branded RNAscope® in situ hybridization (ISH) technology with the launch of several new and updated assays. The developments increase both access to, and use of, RNAscope and improve overall robustness and ease-of-use.... Read more

BIRAC and PerkinElmer Sign Letter of Intent to Promote India-Led Startups and Innovations

NEW DELHI–(BUSINESS WIRE)–The Biotechnology Industry Research Assistance Council (BIRAC) celebrated its 6th Foundation Day on Tuesday in New Delhi. The event, aptly themed ‘Sustaining Innovation: A Market Driven Pathway’, was presided over by the Hon’ble Minister of State for Science and Technology & Earth Sciences, Dr Harsh Vardhan, Prof. Ashutosh Sharma, Secretary, Department of Biotechnology... Read more

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany

Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany New site will support complex clinical research and bring more than 200 new jobs to community RHEINFELDEN, Germany, March 16, 2018 /PRNewswire/ — Thermo Fisher Scientific announced today it is expanding its footprint in the European Union and investing $35 million... Read more

MilliporeSigma and Schneider Electric Sign MoU to Advance China’s Biopharmaceutical Industry

MilliporeSigma and Schneider Electric combine capabilities to automate biopharmaceutical process Customers would save time, get greater flexibility with automated solution Shanghai, China, March 5, 2018 — MilliporeSigma, a leading science and technology company, and Schneider Electric, a global specialist in energy management and automation, announced the signing of a Memorandum of Understanding (MoU) that aims to automate... Read more